Core Insights - Wall Street anticipates a year-over-year decline in earnings for Intuitive Machines, Inc. despite higher revenues in the upcoming earnings report for the quarter ended September 2025 [1] - The stock price may react positively if the actual results exceed expectations, while a miss could lead to a decline [2] Financial Expectations - The consensus estimate indicates a quarterly loss of $0.04 per share, reflecting a significant year-over-year change of -300% [3] - Expected revenues are projected at $62.41 million, representing a 6.7% increase from the same quarter last year [3] Estimate Revisions - The consensus EPS estimate has been revised 18.68% higher in the last 30 days, indicating a reassessment by analysts [4] - It is important to note that aggregate changes may not represent the direction of revisions by individual analysts [4] Earnings Prediction Model - The Zacks Earnings ESP model compares the Most Accurate Estimate to the Zacks Consensus Estimate, providing insights into potential earnings surprises [7][8] - A positive Earnings ESP reading suggests a likely deviation from the consensus estimate, particularly indicating a potential earnings beat [9] Predictive Power of Earnings ESP - A positive Earnings ESP is a strong indicator of an earnings beat, especially when combined with a Zacks Rank of 1 (Strong Buy), 2 (Buy), or 3 (Hold) [10] - Research indicates that stocks with this combination achieve a positive surprise nearly 70% of the time, enhancing the predictive power of Earnings ESP [10]

Core Insights - Wall Street anticipates a year-over-year increase in earnings for Bitfarms Ltd. due to higher revenues, with a focus on how actual results will compare to estimates [1][2] - The upcoming earnings report on November 13 is crucial for stock movement, with better-than-expected results likely to drive the stock higher, while misses could lead to declines [2] Financial Expectations - The consensus estimate indicates a quarterly loss of $0.02 per share, reflecting a year-over-year improvement of 77.8% [3] - Expected revenues are projected at $83.11 million, representing an 85.3% increase from the same quarter last year [3] Estimate Revisions - The consensus EPS estimate has been revised down by 50% over the last 30 days, indicating a reassessment by analysts [4] - It is important to note that the direction of estimate revisions may not always align with the aggregate change [4] Earnings Prediction Model - The Zacks Earnings ESP model compares the Most Accurate Estimate to the Zacks Consensus Estimate, providing insights into potential earnings surprises [7][8] - A positive Earnings ESP reading suggests a likely deviation from the consensus estimate, particularly effective for positive readings [9] Predictive Power of Earnings ESP - A positive Earnings ESP is a strong indicator of an earnings beat, especially when combined with a Zacks Rank of 1 (Strong Buy), 2 (Buy), or 3 (Hold) [10] - Research indicates that stocks with this combination achieve a positive surprise nearly 70% of the time, enhancing the predictive power of Earnings ESP [10]

Core Viewpoint - The market anticipates Nu Holdings Ltd. (NU) to report a year-over-year increase in earnings driven by higher revenues for the quarter ended September 2025, with actual results being crucial for stock price movement [1][2]. Earnings Expectations - The consensus estimate for Nu's quarterly earnings is $0.15 per share, reflecting a year-over-year increase of +25% [3]. - Expected revenues are projected at $4.04 billion, which is a 37.2% increase from the same quarter last year [3]. Estimate Revisions - The consensus EPS estimate has remained unchanged over the last 30 days, indicating stability in analyst expectations [4]. - The Most Accurate Estimate aligns with the Zacks Consensus Estimate, resulting in an Earnings ESP of 0%, suggesting no recent differing analyst views [12]. Earnings Surprise Prediction - The Zacks Earnings ESP model indicates that a positive Earnings ESP is a strong predictor of an earnings beat, especially when combined with a Zacks Rank of 1 (Strong Buy), 2 (Buy), or 3 (Hold) [10]. - Stocks with a positive Earnings ESP and a solid Zacks Rank have historically produced a positive surprise nearly 70% of the time [10]. Historical Performance - In the last reported quarter, Nu was expected to post earnings of $0.13 per share but exceeded expectations with earnings of $0.14, resulting in a surprise of +7.69% [13]. - Over the past four quarters, Nu has beaten consensus EPS estimates two times [14]. Conclusion - While Nu does not appear to be a compelling earnings-beat candidate, it is essential for investors to consider other factors when making investment decisions ahead of the earnings release [17].

Core Viewpoint - Fidelis Insurance Holdings (FIHL) is anticipated to report a year-over-year increase in earnings driven by higher revenues for the quarter ended September 2025, with the actual results being a significant factor influencing its near-term stock price [1][2]. Earnings Expectations - The upcoming earnings report is expected to reveal quarterly earnings of $1.60 per share, reflecting a year-over-year increase of +73.9%, with revenues projected at $758.54 million, up 10.5% from the previous year [3]. - The stock may experience upward movement if these key figures exceed expectations, while a miss could lead to a decline [2]. Estimate Revisions - The consensus EPS estimate has been revised down by 8.37% over the last 30 days, indicating a reassessment by analysts [4]. - The Most Accurate Estimate for Fidelis Insurance aligns with the Zacks Consensus Estimate, resulting in an Earnings ESP of 0%, suggesting no recent differing analyst views [12]. Earnings Surprise Prediction - The Zacks Earnings ESP model indicates that a positive or negative reading can predict deviations from consensus estimates, with a positive ESP being a strong indicator of an earnings beat, especially when combined with a Zacks Rank of 1, 2, or 3 [9][10]. - Fidelis Insurance currently holds a Zacks Rank of 3, making it challenging to predict an earnings beat conclusively [12]. Historical Performance - In the last reported quarter, Fidelis Insurance was expected to post a loss of $0.12 per share but instead delivered earnings of $0.12, resulting in a surprise of +200.00% [13]. - Over the past four quarters, the company has consistently beaten consensus EPS estimates [14]. Conclusion - While the potential for an earnings beat exists, other factors may influence stock movement, and the company does not currently appear to be a compelling earnings-beat candidate [15][17].

Core Viewpoint - Wall Street anticipates a year-over-year increase in earnings for MeiraGTx Holdings PLC despite lower revenues, with actual results being crucial for stock price movement [1][2]. Earnings Expectations - The upcoming earnings report is expected to show a quarterly loss of $0.50 per share, reflecting a year-over-year change of +7.4%, while revenues are projected to be $4.08 million, down 62.6% from the previous year [3]. - The consensus EPS estimate has been revised 6.14% higher in the last 30 days, indicating a reassessment by analysts [4]. Earnings Surprise Prediction - The Zacks Earnings ESP model suggests that a positive Earnings ESP of +2.00% indicates a likelihood of beating the consensus EPS estimate, although the stock currently holds a Zacks Rank of 3 [12]. - Historical performance shows that MeiraGTx has beaten consensus EPS estimates only once in the last four quarters, with a recent surprise of +7.69% when it reported a loss of -$0.48 instead of the expected -$0.52 [13][14]. Industry Context - X4 Pharmaceuticals, another player in the biomedical and genetics sector, is expected to report a loss of $0.79 per share, with revenues projected at $1.9 million, reflecting a year-over-year increase of 239.3% [18]. - Despite a recent upward revision of 14.6% in EPS estimates for X4 Pharmaceuticals, it has a negative Earnings ESP of -80.32%, complicating predictions for beating consensus estimates [19][20].

Core Viewpoint - Silvaco Group, Inc. (SVCO) is anticipated to report flat earnings with a quarterly loss of $0.06 per share, while revenues are expected to increase by 46.5% to $16.07 million compared to the previous year [1][3]. Earnings Expectations - The upcoming earnings report is scheduled for November 12, and the stock may rise if the actual results exceed expectations, while a miss could lead to a decline [2]. - The consensus EPS estimate has been revised 280% higher in the last 30 days, indicating a significant reassessment by analysts [4]. Earnings Surprise Prediction - The Zacks Earnings ESP model shows that the Most Accurate Estimate matches the Zacks Consensus Estimate, resulting in an Earnings ESP of 0%, suggesting no recent differing analyst views [12]. - The stock currently holds a Zacks Rank of 3, making it challenging to predict an earnings beat conclusively [13]. Historical Performance - In the last reported quarter, Silvaco Group was expected to post a loss of $0.09 per share but actually reported a loss of $0.16, resulting in a surprise of -77.78% [14]. - Over the past four quarters, the company has only beaten consensus EPS estimates once [15]. Conclusion - Silvaco Group, Inc. does not appear to be a strong candidate for an earnings beat, and investors should consider other factors when making decisions regarding this stock ahead of the earnings release [18].

Core Viewpoint - Wall Street anticipates a year-over-year increase in earnings for Smith Micro Software, Inc. despite lower revenues, with actual results being crucial for stock price movement [1][2]. Earnings Expectations - The consensus estimate indicates a quarterly loss of $0.13 per share, reflecting a year-over-year improvement of +56.7% [3]. - Expected revenues are projected at $4.4 million, which is a decline of 5.4% compared to the same quarter last year [3]. Estimate Revisions - The consensus EPS estimate has been revised 5% higher in the last 30 days, indicating a reassessment by analysts [4]. - It is important to note that the direction of estimate revisions may not always align with the overall change in consensus estimates [4]. Earnings Surprise Prediction - The Zacks Earnings ESP model compares the Most Accurate Estimate to the Zacks Consensus Estimate, suggesting that recent revisions may provide more accurate predictions [8]. - A positive Earnings ESP reading is a strong indicator of potential earnings beats, especially when combined with a favorable Zacks Rank [10].

Core Viewpoint - Bolt Biotherapeutics, Inc. (BOLT) is anticipated to report a year-over-year increase in earnings despite lower revenues for the quarter ending September 2025, with actual results being a significant factor influencing its near-term stock price [1][2]. Earnings Expectations - The consensus estimate indicates a quarterly loss of $5.07 per share, reflecting a year-over-year change of +36.6%, while revenues are projected to be $0.77 million, down 32.5% from the previous year [3]. - The consensus EPS estimate has been revised 0.83% lower in the last 30 days, indicating a reassessment by analysts [4]. Earnings Surprise Prediction - The Zacks Earnings ESP model shows that the Most Accurate Estimate for Bolt Biotherapeutics is higher than the Zacks Consensus Estimate, resulting in an Earnings ESP of +0.33%, suggesting a bullish outlook on earnings prospects [12]. - The stock currently holds a Zacks Rank of 3, indicating a likelihood of beating the consensus EPS estimate [12]. Historical Performance - In the last reported quarter, Bolt Biotherapeutics was expected to post a loss of $6.4 per share but actually reported a loss of -$4.46, achieving a surprise of +30.31% [13]. - Over the past four quarters, the company has surpassed consensus EPS estimates two times [14]. Industry Context - In the Zacks Medical - Biomedical and Genetics industry, Protagonist Therapeutics (PTGX) is expected to report a loss of $0.59 per share for the same quarter, with a year-over-year change of -9.3% and projected revenues of $10 million, up 113.7% from the previous year [18][19]. - Protagonist Therapeutics has a higher Most Accurate Estimate leading to an Earnings ESP of +29.92%, suggesting a strong likelihood of beating the consensus EPS estimate [19][20].

Core Viewpoint - Wall Street anticipates a year-over-year increase in earnings for Ovid Therapeutics, driven by higher revenues, but actual results compared to estimates will significantly influence the stock price [1][2]. Earnings Expectations - Ovid Therapeutics is expected to report a quarterly loss of $0.15 per share, reflecting a year-over-year change of +25% [3]. - Revenues are projected to be $0.34 million, representing a 100% increase from the same quarter last year [3]. Estimate Revisions - The consensus EPS estimate has been revised 5.26% higher in the last 30 days, indicating a reassessment by analysts [4]. - The Most Accurate Estimate for Ovid is lower than the Zacks Consensus Estimate, resulting in an Earnings ESP of -4.50%, suggesting a bearish outlook from analysts [12]. Earnings Surprise Prediction - The Zacks Earnings ESP model indicates that a positive or negative reading can predict deviations from consensus estimates, with positive readings being more reliable [9][10]. - Ovid's current Zacks Rank is 3, which complicates predictions of an earnings beat [12]. Historical Performance - In the last reported quarter, Ovid was expected to post a loss of $0.16 per share but actually reported a loss of -$0.06, achieving a surprise of +62.50% [13]. - Over the past four quarters, Ovid has beaten consensus EPS estimates two times [14]. Industry Context - Avidity Biosciences, a peer in the Zacks Medical - Biomedical and Genetics industry, is expected to report a loss of $1.05 per share, indicating a year-over-year change of -61.5% [18]. - Avidity's revenue is expected to be $2.5 million, up 6.8% from the previous year, but it also has a negative Earnings ESP of -9.35% [19][20].

Core Viewpoint - The market anticipates that Sky Harbour Group Corporation (SKYH) will report flat earnings compared to the previous year, with revenues expected to increase significantly [1][3]. Earnings Expectations - The consensus EPS estimate for Sky Harbour Group is a loss of $0.10 per share, unchanged from the year-ago quarter, while revenues are projected to be $8.63 million, reflecting a 110.5% increase year-over-year [3]. - The earnings report could lead to a stock price increase if actual results exceed expectations, but a miss could result in a decline [2]. Estimate Revisions - Over the last 30 days, the consensus EPS estimate has been revised down by 25%, indicating a bearish sentiment among analysts regarding the company's earnings prospects [4][12]. - The Most Accurate Estimate for Sky Harbour Group is lower than the Zacks Consensus Estimate, resulting in an Earnings ESP of -10.00% [12]. Historical Performance - In the last reported quarter, Sky Harbour Group was expected to post a loss of $0.12 per share but actually reported a loss of $0.10, achieving a surprise of +16.67% [13]. - The company has beaten consensus EPS estimates three times over the last four quarters [14]. Comparative Analysis - Rocket Lab Corporation (RKLB), another player in the aerospace-defense equipment industry, is expected to report a loss of $0.05 per share, with revenues projected at $149.82 million, a 42.9% increase year-over-year [18][19]. - Rocket Lab's consensus EPS estimate has remained unchanged, but a higher Most Accurate Estimate gives it an Earnings ESP of +25.00%, indicating a likely beat of the consensus EPS estimate [19][20].